Biden still pushing for his cancer ‘breakthrough’ dream, but can it work?
Like so many in the world, President Joe Biden has been personally hit by a cancer death after the loss of his son Beau in 2015 to a brain tumor.
Like so many in the world, President Joe Biden has been personally hit by a cancer death after the loss of his son Beau in 2015 to a brain tumor.
Exscientia has raised $100 million to further develop its artificial intelligence drug discovery platform while advancing its proprietary pipeline into clinical trials. The series C saw Exscientia add BlackRock to an investor syndicate already dotted with big names.
Boston Scientific aims to acquire Lumenis’ global surgical laser business, through a $1.07 billion deal that will incorporate its systems for ear, nose and throat procedures and its Moses laser treatment for breaking apart kidney stones.
Janux Therapeutics has raised $56 million to fund development of T-cell engagers (TCEs). The series A will fund preclinical work on TROP-2 and PSMA candidates, positioning Janux to enter the clinic next year.
On the heels of a new partnership with AbbVie, Caribou Biosciences is reeling in $115 million to keep improving its CRISPR technology and shepherd its pipeline of allogeneic, or off-the-shelf, cell therapies into and through the clinic.
A phase 2b clinical trial of Arena Pharmaceuticals’ olorinab has missed its primary endpoint. The cannabinoid receptor 2 agonist failed to reduce abdominal pain in the overall population of irritable bowel syndrome (IBS) patients, but Arena pointed to a subgroup analysis as evidence of efficacy.
It’s been a relatively quiet few years for FogPharma, at least publicly, but now the Cambridge, Massachusetts-based biotech is revealing a major funding round.
Presage Biosciences landed two more biopharma partners in Merck and Maverick Therapeutics and raised another $13 million to expand its tumor microdosing technology. Its new partners will use that tech to assess new anti-cancer medicines in phase 0 trials, a stage in drug development designed to bridge preclinical and clinical work.
AbbVie has landed an option to buy Mitokinin for a neurodegenerative disease pipeline led by a Parkinson’s disease prospect. The option positions AbbVie to buy Mitokinin upon the completion of IND-enabling studies on the biotech’s lead PINK1 compound.
Virtual drug design tech firm Iktos has set up a new pact with Big Pharma Pfizer to tap its artificial intelligence for its discovery work.